XBiotech Identifies “Super Bloods” for the Development of a True Human™ COVID-19 Therapy

    NEXT STORY
    Delcath Systems Announces Pricing of $22 Million Public Offering and Uplisting to the Nasdaq Capital Market
    PREV STORY
    1Life Healthcare (One Medical) Announces Date of its First Quarter 2020 Results Conference Call
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Aduro Biotech to Present at JP Morgan Healthcare Conference

    BERKELEY, Calif., Jan. 07, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced ...

    author_avatar
    NASDAQ Market News

    Ultragenyx and Kyowa Kirin Announce Publication of Phase 2 Study Results Demonstrating that Crysvita® (burosumab) Improved Outcomes in Children with X-linked Hypophosphatemia in the New England Journal of Medicine

    Pediatric Study Demonstrated Improvements in Rickets Severity, Growth, Pain and Physical Activity in Children ...

    author_avatar
    NASDAQ Market News

    BeiGene Presents Updated Head to Head Results from Phase 3 Trial of Zanubrutinib vs. Ibrutinib in Patients with Waldenström’s Macroglobulinemia at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program

    author_avatar
    NASDAQ Market News